GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Increasing evidence indicates that obesity is highly associated with chronic kidney disease (CKD). GLP-1 receptor (GLP-1R) agonist has shown benefits on kidney diseases, but its direct role on kidney metabolism in obesity is still not clear. This study aims to investigate the protection and metabolic modulation role of liraglutide (Lira) on kidney of obesity. Rats were induced obese by high-fat diet (HFD), and renal function and metabolism changes were evaluated by metabolomic, biological and histological methods. HFD rats exhibited systemic metabolic disorders such as obesity, hyperlipidemia and impaired glucose tolerance, as well as renal histological and function damages, while Lira significantly ameliorated these adverse effects in HFD rats. Metabolomic data showed that Lira directly reduced renal lipids including fatty acid residues, cholesterol, phospholipids and triglycerides, and improved mitochondria metabolites such as succinate, citrate, taurine, fumarate and nicotinamide adenine dinucleotide (NAD+) in the kidney of HFD rats. Furthermore, we revealed that Lira inhibited renal lipid accumulation by coordinating lipogenic and lipolytic signals, and partly rescued renal mitochondria function via Sirt1/AMPK/PGC1α pathways in HFD rats. This study suggested that Lira alleviated HFD-induced kidney injury at least partly via directly restoring renal metabolism, thus GLP-1R agonist is a promising therapy for obesity-associated CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Further studies in obese non-diabetic models have also identified renoprotection with GLP-1 receptor agonists (71), thus stimulating investigations into a potential clinical role for such agents in obesity-associated kidney disease in the absence of overt diabetes, as indicated below.”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [71]
In the citing paper
“They minimize renal hypoxic-ischaemic damage as they regulate the mitochondrial activity of renal cells [40];”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxyl radicals, redox-sensitive signalling cascades and antioxidants
Genestra, M. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.04.009 · Cited by 4,930
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
Kovesdy, C. P., Furth, S. L., Zoccali, C., & on behalf of the World Kidney Day Steering Committee (2017) · American Journal of Nephrology · doi:10.1159/000458467 · Cited by 2,217
Regulation of inflammation by short chain fatty acids
Vinolo, M. A. R., Rodrigues, H. G., Nachbar, R. T., & Curi, R. (2011) · Nutrients · doi:10.3390/nu3100858 · Cited by 1,724
PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure
Cantó, C., & Auwerx, J. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328328d0a4 · Cited by 1,624
NAD+ and sirtuins in aging and disease
Imai, S.-I., & Guarente, L. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.04.002 · Cited by 1,481
Body Mass Index and Risk for End-Stage Renal Disease
Hsu, C.-Y., McCulloch, C. E., Iribarren, C., Darbinian, J., & Go, A. S. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-1-200601030-00006 · Cited by 1,390
Predictors of New-Onset Kidney Disease in a Community-Based Population
Fox, C. S. (2004) · JAMA · doi:10.1001/jama.291.7.844 · Cited by 1,241
Novel insights of dietary polyphenols and obesity
Wang, S., Moustaid-Moussa, N., Chen, L., Mo, H., Shastri, A., Su, R., Bapat, P., Kwun, I., & Shen, C.-L. (2014) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.09.001 · Cited by 896
Obesity and Risk of Type 2 Diabetes and Cardiovascular Disease in Children and Adolescents
Goran, M. I., Ball, G. D. C., & Cruz, M. L. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021442 · Cited by 735
Association between obesity and kidney disease: A systematic review and meta-analysis
Wang, Y., Chen, X., Song, Y., Caballero, B., & Cheskin, L. J. (2008) · Kidney International · doi:10.1038/sj.ki.5002586 · Cited by 687
Cited by
Items 101–110 of 110
Karagiannidis, A. G. (2023) · University of Thessaly Institutional Repository (University of Thessaly) · doi:10.26253/heal.uth.39000
Therapeutic effect and underlying mechanism of emodin on renal injury
Mitra, P., Jana, S., Modak, B. S., & Roy, S. (2026) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2026.100757
Sun, Y., Wang, X., Liu, H., Zhou, X., & Ma, Q. (2026) · Foods · doi:10.3390/foods15050806
CYR61 promotes obesity-induced kidney injury by activating endoplasmic reticulum stress
Li, B., Lv, H., Gong, K., Gao, Y., Zhen, J., & Hu, Z. (2026) · Molecular Immunology · doi:10.1016/j.molimm.2026.03.005
Shu-yin, Y., Deng, Q., Gao, H.-J., Liu, H.-D., Tang, H., Wang, Q., Liu, Y.-M., & Yan, Q.-B. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1862366 · Cited by 1
“The underlying mechanism involves activation of the AMPK/SIRT1 energy signaling axis in target cells, including hepatic stellate cells and cardiomyocytes (Wang et al., 2018).”
Keeping it acid ceramidase: How adiponectin protects in the glomerulus
Frambes, N. I., Taylor, E. B., Sullivan, J. C., & Ryan, M. J. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.104979
Wang, F., Li, Q., Wen, Q., Su, B., Zhou, H., Fu, Y., Chen, H., & He, Q. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1903973
“…validated preclinical evidence for mitochondrial biogenesis mediated by GLP-1R and organ protection dependent on PGC-1 α across multiple metabolically relevant tissues, including the kidney (Elkhoely, 2023; Wang et al., 2018), adipose tissue (Zhou et al., 2019) and myocardium (Zhang et al., 2021).”
InfluentialImpact of renal lipid droplet dynamics on tubular health
Heneberg, P., & Šimčíková, D. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101101
“GLP-1 receptor agonists such as liraglutide reduce tubular LD accumulation and increase the expression of mitochondrial markers in experimental obesity-associated kidney injury (57).”
New Insights into the Role of Mitochondrial Dysfunction in Diabetic Kidney Disease in the Omics Era
Liu, X. K., Zhou, X. L., & Xia, W. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s622389
“108,109”
Liu, F., Xu, Z., Wang, W., Gao, J., Changgeng, F. U., & Liu, P. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1996288
“These effects were accompanied by improvements in SIRT1–AMPK–PGC-1 α signalling, the NAD + /NADH ratio, and ATP production, ultimately attenuating albuminuria, glomerulosclerosis, and interstitial fibrosis (Wang et al., 2018).”
Metadata
- Authors
- Wang, C., Li, L., Liu, S., Liao, G., Li, L., Chen, Y., Cheng, J., Lu, Y., & Liu, J.
- Affiliations
- Sichuan University (CN)
- Corresponding author
- Lu, Yanrong
- Liu, Jingping
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-03-28
- Volume
- 13
- Issue
- 3
- Pages
- e0193473
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5873987
- OpenAlex
- W2795005430
- Cited by
- 110
- References
- 48
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 13 · 2023: 12 · 2022: 14 · 2021: 14 · 2020: 15 · 2019: 12 · 2018: 1
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Natural Science Foundation of China (31200754, 81571808)
- China Postdoctoral Science Foundation (2012M511931)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- GLP-1 receptor agonists, liraglutide, obesity, chronic kidney disease, renal metabolism, high-fat diet, renal lipid accumulation, mitochondrial function, hyperlipidemia, impaired glucose tolerance
- MeSH terms
- Liraglutide, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Fibrosis, Homeostasis, Kidney, Male, Mitochondria, Obesity, Signal Transduction, Rats, Sprague-Dawley, Lipid Metabolism, Rats, AMP-Activated Protein Kinases, Metabolomics, Sirtuin 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.